MedChunk
Medically reviewed

Atrial Fibrillation Treatment During Pregnancy

Learn how atrial fibrillation is treated during pregnancy, including pregnancy-safe medications, heart rhythm control, cardioversion, blood thinners, and delivery planning.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 15 min read

Atrial fibrillation during pregnancy can be treated with carefully selected medicines, electrical cardioversion, and blood-thinning treatment when needed. The treatment plan aims to control the mother's heart rhythm or heart rate, reduce the risk of stroke, and protect the developing baby. Cardiologists and obstetric specialists work together to choose treatments that balance benefits and risks for both.

How is atrial fibrillation managed during pregnancy?

Atrial fibrillation (AF) is an irregular heart rhythm in which the upper chambers of the heart beat in an uncoordinated way. During pregnancy, managing this condition requires additional care because some heart medicines can affect fetal growth or development, while untreated AF may create risks for the mother and baby.

Unlike routine AF management outside pregnancy, doctors must consider the stage of pregnancy, the mother's heart health, the duration of the abnormal rhythm, and the possibility of blood clots.

The main treatment approaches include:

  • Heart rate control: Medicines slow the heart rate when AF continues.
  • Heart rhythm control: Medicines or electrical cardioversion may help restore a normal heart rhythm.
  • Stroke prevention: Anticoagulants, also called blood thinners, may be recommended when the risk of blood clots is high enough.
  • Maternal and fetal monitoring: Regular assessments help doctors evaluate treatment effects and pregnancy progress.

The 2025 European Society of Cardiology (ESC) Guidelines for cardiovascular disease and pregnancy identify rhythm control as the preferred AF treatment strategy during pregnancy, while recognizing that rate control may be appropriate in selected circumstances.

Which heart medicines can be used during pregnancy?

Medication selection depends on whether the immediate goal is to slow the heart rate, restore a normal rhythm, or prevent blood clots. Doctors consider the available pregnancy safety information before prescribing any medicine.

Beta-blockers for controlling heart rate

Beta-blockers reduce the effects of stress hormones on the heart. They can slow the heartbeat and help control the rapid heart rate associated with AF.

Metoprolol and propranolol are examples of beta-blockers that may be considered during pregnancy. Metoprolol is commonly used when heart rate control is needed.

However, beta-blockers require appropriate monitoring. Their use during pregnancy has been associated with concerns about reduced fetal growth in some circumstances. Doctors may arrange additional ultrasound assessments to monitor the baby's growth when clinically appropriate.

Atenolol is generally avoided during pregnancy because of concerns about its association with restricted fetal growth.

The 2023 American College of Cardiology and American Heart Association AF guidelines identify beta-blockers such as metoprolol and propranolol as reasonable first-line options for rate control in pregnant patients with persistent AF.

Digoxin when beta-blockers are unsuitable

Digoxin is another medicine that can help slow the heart rate. It may be considered when beta-blockers do not provide enough control or cannot be used.

Doctors may prescribe digoxin alone or alongside a beta-blocker, depending on the patient's circumstances. Its effects and dosing need careful assessment during pregnancy.

Pregnancy can also affect how digoxin blood levels are measured. Therefore, healthcare professionals interpret laboratory results alongside the patient's clinical condition rather than relying on a single measurement.

Flecainide and sotalol for maintaining a normal rhythm

Some pregnant patients need treatment aimed at restoring or maintaining a normal heart rhythm rather than simply slowing the heartbeat.

Flecainide and sotalol are antiarrhythmic medicines that may be considered in selected patients, particularly when the heart has no significant structural abnormality.

These medicines are not suitable for everyone. Doctors assess heart structure, electrical activity, other medical conditions, and possible medication interactions before prescribing them.

Sotalol also has beta-blocking effects, so monitoring fetal growth may be appropriate during treatment. Electrocardiograms (ECGs) may be used to monitor the mother's heart rhythm and electrical intervals while taking antiarrhythmic medicines.

According to the 2023 Heart Rhythm Society (HRS) Expert Consensus Statement on Arrhythmias During Pregnancy, treatment decisions should account for the potential effects of antiarrhythmic medicines on both the mother and fetus. The lowest effective dose and regular reassessment are important considerations.

Which medicines are generally avoided?

Some antiarrhythmic and anticoagulant medicines have important pregnancy-related safety concerns.

  • Amiodarone: Generally avoided because of potential fetal effects, including thyroid problems, slowed heart rate, impaired growth, and developmental concerns. It may be reserved for life-threatening arrhythmias when other options are unsuitable.
  • Atenolol: Generally avoided because of concerns about restricted fetal growth.
  • Direct oral anticoagulants (DOACs): Medicines such as apixaban, rivaroxaban, dabigatran, and edoxaban are not recommended during pregnancy because their safety and effectiveness have not been established adequately.

Anyone already taking an AF medicine before pregnancy should have it reviewed promptly. Prescribed medicines should not be stopped or changed without medical guidance, because sudden changes can also create risks.

Is electrical cardioversion safe during pregnancy?

Electrical cardioversion is a procedure that uses a controlled electrical shock to restore a normal heart rhythm. It can be performed during pregnancy when clinically necessary and is considered safe for the mother and fetus when appropriately managed.

Doctors may recommend cardioversion when:

  • AF causes unstable blood pressure or other signs of poor circulation.
  • The heart rate remains dangerously fast despite initial treatment.
  • Symptoms continue despite medication.
  • Restoring a normal rhythm is considered important for maternal or fetal well-being.

During the procedure, the patient receives appropriate sedation. The medical team monitors the mother's heart and circulation, with fetal heart rate monitoring during and after the procedure when appropriate for the stage of pregnancy.

Pregnancy is not a reason to delay emergency cardioversion when the mother's condition requires it. The electrical shock is delivered to the mother's heart, and the treatment is performed using the same essential cardioversion principles used outside pregnancy.

The American College of Cardiology and American Heart Association clinical practice guideline states that direct-current cardioversion is safe for pregnant patients and their fetuses and should be performed when indicated.

Do pregnant women with atrial fibrillation need blood thinners?

Not everyone with AF needs anticoagulant medication during pregnancy. Doctors assess the likelihood of blood clots and stroke before deciding whether blood-thinning treatment is necessary.

AF can allow blood to collect in parts of the heart, particularly the left atrium, increasing the possibility of clot formation. Pregnancy also increases the body's tendency to form blood clots, which makes individual risk assessment particularly important.

How doctors decide whether anticoagulation is needed

The decision depends on several factors, including:

  • Previous stroke or transient ischemic attack (TIA).
  • Existing heart disease or heart failure.
  • High blood pressure or diabetes.
  • Age and other cardiovascular risk factors.
  • Heart valve conditions, particularly mitral stenosis.
  • Whether AF is persistent or associated with other significant heart abnormalities.

Doctors may use established stroke-risk assessment tools as part of their evaluation. However, commonly used scoring systems have not been fully validated for pregnant patients. The results must therefore be interpreted carefully alongside pregnancy-related risks.

Which blood thinners may be considered?

The choice of anticoagulant depends on the reason for treatment, the stage of pregnancy, and the mother's underlying heart condition.

Low-molecular-weight heparin (LMWH): This injectable anticoagulant is commonly used when anticoagulation is needed during pregnancy. It does not cross the placenta, making it an important option for preventing maternal blood clots.

Unfractionated heparin: This anticoagulant may be used in selected situations, including around delivery, because its effects can be adjusted and reversed more rapidly than those of LMWH.

Warfarin: Warfarin crosses the placenta and can cause fetal harm, particularly during early pregnancy. However, selected patients with very high clotting risks, especially those with mechanical heart valves, may require specialist anticoagulation strategies involving vitamin K antagonists or heparin at different stages of pregnancy.

These decisions are particularly complex and should be made by specialists experienced in pregnancy and cardiovascular disease.

Direct oral anticoagulants, including apixaban and rivaroxaban, are generally avoided during pregnancy because adequate safety evidence is lacking.

The 2024 ESC Guidelines for the management of atrial fibrillation discuss pregnancy-specific anticoagulation considerations, including the use of heparins or vitamin K antagonists in selected patients with elevated thromboembolic risk.

Does atrial fibrillation treatment change during each trimester?

The main treatment goals remain similar throughout pregnancy, but the timing of medication exposure, fetal development, and delivery planning can influence which treatments are appropriate.

First trimester

The first trimester is an important period of fetal organ development. Doctors carefully review the safety of medicines before starting or continuing antiarrhythmic treatment.

When medication is necessary, specialists select an appropriate drug and dose after considering the mother's heart condition and potential fetal effects. If possible, medicines with established pregnancy safety experience are preferred.

Anticoagulation decisions also require particular attention because warfarin exposure during early pregnancy may harm fetal development. Patients who require anticoagulation for significant cardiovascular conditions need an individualized plan rather than stopping treatment independently.

Second trimester

During the second trimester, doctors continue monitoring heart rhythm, heart rate, medication effects, and fetal growth.

Patients taking beta-blockers or other antiarrhythmic medicines may need follow-up ECGs and pregnancy assessments. If anticoagulation is required, the medication and dose are reviewed according to the mother's clotting risk and treatment needs.

Third trimester

As pregnancy approaches delivery, the medical team focuses on maintaining stable heart rhythm and circulation while preparing for childbirth.

Anticoagulant timing becomes particularly important because these medicines can increase bleeding risks during delivery. Doctors may adjust treatment or temporarily change anticoagulants according to the patient's clinical circumstances.

Delivery planning should involve cardiology, obstetrics, and anesthesia specialists when significant AF or associated heart disease is present.

Can a woman with atrial fibrillation have a normal delivery?

Yes. Many women with atrial fibrillation can have a vaginal delivery, depending on their heart condition, rhythm stability, and overall pregnancy health.

AF alone does not automatically mean that a cesarean delivery is necessary. The method of delivery is decided according to maternal and obstetric factors rather than the rhythm diagnosis alone.

The medical team considers:

  • Whether the heart rhythm is stable.
  • Whether there is significant underlying heart disease.
  • Whether the mother is taking anticoagulants.
  • The possibility of bleeding complications.
  • The mother's ability to tolerate the physical demands of labor.
  • Whether additional cardiac monitoring or anesthesia support is needed.

For patients receiving anticoagulants, a clear plan is needed for when to pause, adjust, or restart medication. This is also important when considering epidural or spinal anesthesia because anticoagulant use can affect the safety and timing of these procedures.

A cesarean delivery may be recommended for obstetric reasons or specific maternal cardiac circumstances. The decision should be individualized rather than based on AF alone.

Is catheter ablation performed during pregnancy?

Catheter ablation is a procedure that uses thin tubes inserted into blood vessels to locate and treat the heart tissue responsible for an abnormal rhythm.

For most patients with AF during pregnancy, catheter ablation is postponed until after delivery. This is because the procedure may involve imaging radiation, specialized equipment, and additional procedural considerations.

However, ablation may occasionally be considered when arrhythmias are difficult to control with medication and create significant risks for the mother or fetus.

In such situations, experienced specialist centers may use techniques that minimize or avoid fluoroscopy, which is the type of X-ray imaging commonly used during catheter procedures.

The decision requires careful consideration of the potential benefits, procedural risks, and available alternatives.

How are the mother and baby monitored during treatment?

Monitoring helps doctors assess whether treatment is controlling AF without causing unwanted effects for the mother or developing baby.

The exact monitoring schedule depends on the mother's condition, the medicines being used, and the stage of pregnancy.

Monitoring the mother's heart

Doctors may use several assessments to evaluate the effectiveness of treatment:

  • Electrocardiogram (ECG): Records the electrical activity of the heart and helps identify AF and other rhythm changes.
  • Holter monitoring: Records heart activity continuously over a period of time to identify episodes of abnormal rhythm.
  • Echocardiogram: Uses ultrasound to assess heart structure, pumping function, and valve abnormalities.
  • Blood tests: May help assess thyroid function, electrolyte levels, and other factors relevant to heart rhythm and medication safety.
  • Blood pressure and pulse checks: Help assess the mother's response to treatment.

Monitoring the baby's health

Depending on the treatment and pregnancy stage, fetal monitoring may include:

  • Ultrasound examinations to assess fetal growth.
  • Fetal heart rate monitoring when clinically appropriate.
  • Additional assessments if there are concerns about fetal development or maternal circulation.

Women taking medicines such as sotalol or beta-blockers may need particular attention to fetal growth. The medical team determines whether additional assessments are necessary.

What happens after delivery?

AF treatment does not necessarily end after childbirth. Some women continue to need medication, rhythm monitoring, or anticoagulation during the postpartum period.

Doctors reassess the heart rhythm and review whether existing medicines remain necessary. Medication doses may need adjustment as pregnancy-related changes in the body resolve.

Breastfeeding also influences medication selection. Some antiarrhythmic and anticoagulant medicines may be compatible with breastfeeding, while others require additional caution because of possible exposure through breast milk.

Women taking anticoagulants need a clear plan for restarting treatment after delivery, taking bleeding risks and the method of delivery into account.

Follow-up with a cardiologist is important, particularly when AF was persistent, associated with structural heart disease, or required treatment during pregnancy.

When should a pregnant woman with atrial fibrillation seek urgent medical care?

New or worsening symptoms during pregnancy should be assessed promptly, especially when AF is already known or suspected.

Examples of concerning symptoms include:

  • Persistent or unusually rapid heartbeat.
  • Chest pain or pressure.
  • Shortness of breath, particularly at rest.
  • Severe dizziness or fainting.
  • Sudden weakness or difficulty speaking.
  • Sudden changes in vision or other possible signs of stroke.

Chest pain, severe breathing difficulty, fainting, or sudden neurological symptoms require emergency medical assessment. A known diagnosis of AF should not be used to assume that new symptoms are caused by the same rhythm problem.

Why is a multidisciplinary treatment team important?

Atrial fibrillation during pregnancy involves decisions about heart rhythm, blood clot prevention, medication safety, fetal development, and childbirth. These areas often require input from different medical specialists.

The care team may include:

  • Cardiologist: Evaluates the heart condition and plans rhythm or rate control.
  • Electrophysiologist: Provides specialist advice about abnormal heart rhythms and advanced treatment options.
  • Obstetrician: Monitors the pregnancy and coordinates delivery planning.
  • Maternal-fetal medicine specialist: Helps manage pregnancies involving additional maternal or fetal risks.
  • Anesthesiologist: Plans anesthesia and pain management, particularly when anticoagulation or significant heart disease is involved.

Shared decision-making helps ensure that treatment choices reflect the mother's health, fetal considerations, and the family's pregnancy and delivery plans.

Although AF during pregnancy requires careful management, several effective treatment options are available. With appropriate specialist care, medication selection, and monitoring, many women can manage the condition throughout pregnancy and plan for childbirth safely.

Frequently Asked Questions

Common questions about managing an irregular heart rhythm, medication safety, and childbirth during pregnancy.

Can atrial fibrillation be treated without medication during pregnancy?

Some women may not need continuous medication if their AF is temporary, their heart rate is stable, and their risk of blood clots is low. However, treatment decisions depend on the underlying heart condition and individual risks. Others may require medication, cardioversion, or anticoagulation to protect their health.

Which is the safest beta-blocker for atrial fibrillation during pregnancy?

Metoprolol and propranolol are commonly considered options for controlling heart rate during pregnancy. The most appropriate medicine depends on the mother's heart condition, other medications, and fetal considerations. Atenolol is generally avoided because of concerns about restricted fetal growth.

Can atrial fibrillation harm an unborn baby?

AF does not automatically mean that a baby will be harmed. However, a rapid or poorly controlled maternal heart rhythm, underlying heart disease, and certain medications may create risks. Appropriate maternal treatment and fetal monitoring help doctors identify and manage potential complications.

Does atrial fibrillation during pregnancy always require blood thinners?

No. Anticoagulation depends on the mother's risk of stroke and other factors, including previous blood clots and underlying heart disease. Pregnancy-specific considerations influence which anticoagulant is appropriate. Direct oral anticoagulants are generally avoided during pregnancy.

Can atrial fibrillation return after childbirth?

Yes. AF may continue or recur after delivery, particularly when an underlying heart condition remains. Some women need ongoing medication, anticoagulation, or specialist follow-up. Treatment should be reviewed after childbirth, including its compatibility with breastfeeding.

Citations

  1. 2025 ESC Guidelines for the Management of Cardiovascular Disease and Pregnancy – European Society of Cardiology
  2. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation – American College of Cardiology and American Heart Association
  3. 2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy – Heart Rhythm Society
  4. 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation – Journal of the American College of Cardiology
  5. 2024 ESC Guidelines for the Management of Atrial Fibrillation – European Society of Cardiology
Share this article